Latest filing published 12 May 2025 for Novonesis (Novozymes A/S), €666k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Anders Lund: trading record in brief
This profile gathers the share dealings of Anders Lund in Novonesis (Novozymes A/S). In total, 4 filings cover trades dated from 6 February 2020 to 12 May 2025.
Every open-market trade on record is a purchase: 4 purchases worth €4.8M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2025, the count stands at 2 purchases and no sales.
A typical purchase (the median) is worth €887k. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The newest entry dates from 12 May 2025: an open-market purchase of €666k, in Novonesis (Novozymes A/S). Half of the filings or more reach the Finanstilsynet DK feed on the day of the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by Finanstilsynet DK. They describe what insiders did and are not a recommendation.
Companies and markets linked to Anders Lund
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 19,934 shares@ DKK 249.400.0% of flowShareOutside a trading venueISIN DK0060336014DK:1362576Canonical exit: 10 Aug 2025 (T+90)
- 26,550 shares@ DKK 249.400.1% of flowShareOutside a trading venueISIN DK0060336014DK:1347415Canonical exit: 4 Jun 2025 (T+90)
- 63,091 shares@ DKK 277.08940.2% of flowShareISIN DK0060336014DK:1028707Canonical exit: 28 Jul 2021 (T+90)
- 32,468 shares@ DKK 203.63630.1% of flowShareISIN DK0060336014DK:920562Canonical exit: 6 May 2020 (T+90)
4 of 4 declarations